- Home
- CISS vs PBM Comparison
CISS vs PBM Comparison
Compare CISS & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- PBM
- Stock Information
- Founded
- CISS 2022
- PBM 1994
- Country
- CISS Greece
- PBM Canada
- Employees
- CISS N/A
- PBM N/A
- Industry
- CISS Marine Transportation
- PBM
- Sector
- CISS Consumer Discretionary
- PBM
- Exchange
- CISS Nasdaq
- PBM NYSE
- Market Cap
- CISS 2.8M
- PBM 2.7M
- IPO Year
- CISS N/A
- PBM N/A
- Fundamental
- Price
- CISS $3.56
- PBM $5.52
- Analyst Decision
- CISS
- PBM
- Analyst Count
- CISS 0
- PBM 0
- Target Price
- CISS N/A
- PBM N/A
- AVG Volume (30 Days)
- CISS 20.6K
- PBM 195.3K
- Earning Date
- CISS 05-15-2025
- PBM 07-07-2025
- Dividend Yield
- CISS N/A
- PBM N/A
- EPS Growth
- CISS N/A
- PBM N/A
- EPS
- CISS N/A
- PBM N/A
- Revenue
- CISS $38,174,754.00
- PBM N/A
- Revenue This Year
- CISS N/A
- PBM N/A
- Revenue Next Year
- CISS N/A
- PBM N/A
- P/E Ratio
- CISS N/A
- PBM N/A
- Revenue Growth
- CISS N/A
- PBM N/A
- 52 Week Low
- CISS $2.85
- PBM $2.93
- 52 Week High
- CISS $25.35
- PBM $701.82
- Technical
- Relative Strength Index (RSI)
- CISS 43.43
- PBM 58.10
- Support Level
- CISS $3.55
- PBM $4.52
- Resistance Level
- CISS $3.83
- PBM $5.80
- Average True Range (ATR)
- CISS 0.17
- PBM 0.93
- MACD
- CISS -0.00
- PBM 0.08
- Stochastic Oscillator
- CISS 1.59
- PBM 39.21
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.